Summary of Ultragenyx Pharmaceutical Conference Call Company Overview - **Company**: Ultragenyx Pharmaceutical (NasdaqGS:RARE) - **Date**: March 11, 2026 - **Key Speaker**: Eric Crombez, CMO Recent Events and Priorities - **Commercial Success**: - Crysvita continues to show double-digit year-over-year growth - Significant growth in Dojolvi and Evkeeza, with Mepsevii contributing to revenue [4][4] - **Pipeline Focus**: - Emphasis on Angelman syndrome with data readout expected in the second half of the year - Progress in gene therapy pipeline, particularly for GSDIa and Sanfilippo [4][4] Angelman Syndrome Study - **Phase 3 Study Design**: - Primary endpoint will be measured without caregiver input to control for placebo effects [6][7] - Previous Phase 1/2 showed a Bayley Cognition Score improvement of over 10, with a clinically significant difference set at 5 [9][13] - **Statistical Considerations**: - Study powered to show a 10.9 difference in cognition scores from baseline in treated patients, with a flat natural history curve for the placebo group [11][12] - **MDRI Endpoint**: - FDA has agreed to consider the Multi-Domain Responder Index (MDRI) as a secondary endpoint, which captures broader developmental aspects [16][18] Gene Therapy Dosing and Efficacy - **Dosing Strategy**: - Initial dosing informed by animal models, with adjustments made based on clinical data from Phase 1/2 [20][21] - **GTX-102 Potency**: - Claimed to be the most potent ASO in development for Angelman, based on clinical data from 74 patients [22][22] - **Knockdown and Protein Restoration**: - Achieving over 80% knockdown is necessary for clinical benefit, with expectations of around 35% expression needed for efficacy [25][27] DTX401 Gene Therapy - **BLA Acceptance**: - BLA for DTX401 accepted, with a PDUFA date set for August [30][30] - **Manufacturing Control**: - In-house manufacturing facility established to ensure quality and control over production [32][33] - **Durability of Treatment**: - Strong durability observed in Phase I/II patients, supporting confidence in FDA review [34][35] Commercial Opportunity - **Market Potential**: - Approximately 6,000 patients in the U.S. with GSDIa, with high penetration expected due to the necessity of treatment [42][42] Wilson Disease Program - **Efficacy Differentiation**: - Aiming to show positive differentiation from existing chelator treatments, with a focus on the majority of patients coming off chelators [48][49] - **Biomarker Confidence**: - Heparan sulfate is considered a strong biomarker for clinical benefit, with a shift towards clinical approval based on patient outcomes [46][47] Conclusion - Ultragenyx is focused on advancing its gene therapy pipeline, particularly for rare diseases like Angelman syndrome and GSDIa, with promising commercial opportunities and a strong emphasis on clinical efficacy and safety in its studies.

Core Argument - Embracing imperfections and mistakes can lead to innovation and discovery [20][21] - What seems like a wrong turn is not always wrong; it can be the path to discovery [20][21] Memory & Cognition - Memory is reconstructive and prone to errors, which can foster creativity and innovative idea generation [4][6][7] - Memory errors contribute to emotional intelligence and adaptation through a process called adaptive forgiveness [7][8] - Synaptic pruning during adolescence, while seemingly a loss, enhances moral reasoning and understanding of the world [11][12] - Mind wandering and daydreaming activate the brain's default mode network, facilitating self-reflection and future planning [14][15][16] The Placebo Effect - The placebo effect demonstrates the brain's ability to heal itself by releasing chemicals like dopamine and endorphins when it believes it is being treated [17][18][19]

[Music] Have you ever started a project, a goal, or even a Netflix series that you just couldn't finish. Or had those moments where you're stuck looking at the mess you're in, wondering why you even start in the first place. Does that sound familiar.Of course it does. You all been there. But what if I told you there's a way to flip the script today.Good morning to our present. My name is Manuel Jones and I'm here to deliver you that answer. But first, I need to take you back 16 years to January 10, 2008 to ...